SNAP's Position on Neutersol
Sean Hawkins, Executive Director
Dr. Jim Weedon, Director of Operations
As with the introduction of any medical procedure resulting from technological advances, the use of Neutersol® has generated many questions both in the veterinary medical and animal welfare communities. Recognized for its innovative and 'best practice' approaches to ending dog and cat overpopulation, the veterinary medical and animal protection policy teams at SNAP have carefully reviewed the use and effects of Neutersol® and developed the following position.
Neutersol® is the first and only FDA approved injectable product for sterilizing male dogs, initially young dogs aged three to ten months. The Neutersol® solution is gently injected into each of the dogs two testes with a fine (28 gauge) needle and can be administered on an outpatient basis. Pain experienced by the puppy from the injection is minimal because of the fine needle that is used to administer the product and the absence of pain receptors inside the testicles. The procedure takes approximately five minutes and does not require the use of general anesthesia. Some patients may benefit from sedation prior to administration of Netersol®
Following administration of Neutersol®, sterilization is essentially 100% (99.6%) effective, permanent and irreversible. There are very few side effects to the use of Neutersol®; the puppy is able to walk and go home immediately after administration.
The utilization of non-surgical sterilants for neutering, such as Neutersol®, is supported by the American Humane Association, Humane Society of the United States, American Society for the Prevention of Cruelty to Animals, American Veterinary Medical Association, and PETsMART Charities.
SNAP has reviewed the clinical research and white papers on Neutersol® (which are available at www.neutersol.com). We feel that we can offer the following opinions on the advantages to animals and the communities working to reduce animal populations through the use of Neutersol®:
The injection of Neutersol® to sterilize animals does not require specialized surgical facilities, equipment or supplies.
Increased operating efficiencies are achieved by utilizing Neutersol®. These include the reduction of veterinarian and staff time, reduction of drug and supply inventory required for traditional neutering procedures, and increasing the number of sterilizations performed.
Utilization of Neutersol® eliminates the risks of anesthesia and post-surgical complications, reduces stress endured by dogs resulting from lengthened stays in the hospital required for traditional surgery, and minimizes required aftercare and therefore client compliance with post-surgical instructions.
In cases where medical issues might make anesthesia and surgery contraindicated, administration of Neutersol® could be a means of sterilization.
Utilization of Neutersol® reduces recovery time of that required for traditional surgery and increases the availability of dogs going home or being placed up for adoption.
Dogs who are sterilized with Neutersol® should be identified by a permanent tattoo or microchip. A Neutersol tag line can be added to all three microchip identification systems currently utilized in the United States.
The FDA has stated that as with surgical castration, secondary male characteristics such as roaming, marking, aggression, and mounting may be displayed in animals who have received Neutersol® injection.
In summary, SNAP endorses the use of Neutersol® injection as an effective, safe, and advantageous approach to our work in reducing pet overpopulation. We encourage the use of Neutersol® and the further development of additional chemical sterilants.